Sagent Pharmaceuticals Launches Cefepime for Injection, USP

SCHAUMBURG, Ill., March 25 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched Cefepime for injection, USP, a broad spectrum antibiotic used to treat bacterial infections. Sagent's Cefepime for injection will be available in 1g and 2g single dose vials. According to IMS data, sales of Cefepime in the United States in 2006 were approximately $167 million. Sagent will begin marketing and shipping cefepime immediately.

"In the past week Sagent has launched two anti-infective products, each upon the expiration of innovator exclusivity. These launches illustrate both Sagent's capabilities and the depth of our unique worldwide partnerships in effectively developing, obtaining approval for, and marketing a broad range of injectable products," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "The addition of Cefepime to our product portfolio, underscores our commitment to rapidly provide our customers and patients with a strong portfolio of injectable antibiotic products."

The introduction of Cefepime for injection marks the fourth product launch from Sagent's pipeline of more than 200 products. This month, the Company has launched two essential antibiotic products: ciprofloxacin injection, USP, 5% dextrose premix bag, a synthetic broad spectrum antimicrobial agent for intravenous administration and Cefazolin for injection, USP.

About Cefepime

Cefepime for injection, USP, is a fourth-generation cephalosporin, an antibiotic used to treat a variety of infections and is the generic equivalent of Elan's MAXIPIME(R). Cefepime for injection, USP, is indicated for infections of the urinary tract, skin and skin structure infections, as well as moderate to severe pneumonia, complicated intra-abdominal infections, and as empiric therapy for febrile neutopenic patients. The most common adverse effects may include headache, nausea, diarrhea, vomiting or rash. Less common adverse effects include cardiovascular events, respiratory effects and dizziness.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with an emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit http://www.SagentPharma.com.

SOURCE Sagent Pharmaceuticals, Inc.

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.